Position of the Transparency Council – Veoza (fezolinetant)

At its meeting on 2 September 2024, the Transparency Council adopted position No. 88/2024 on the appropriateness of issuing reimbursement approvals for the drug Veoza (fezolinetant) for the indication: treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Publication of the position >>